Xeris Biopharma is a biopharmaceutical company that develops and commercializes therapies for chronic endocrine and neurological diseases, with a focus on rare and underserved patient populations. The company markets three FDA-approved products: Recorlev, a cortisol synthesis inhibitor for Cushing's syndrome; Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia in diabetes patients; and Keveyis, a treatment for primary periodic paralysis. Beyond commercial products, Xeris operates an advancing pipeline anchored by XP-8121, a once-weekly subcutaneous levothyroxine candidate, and leverages proprietary formulation platforms—XeriSol and XeriJect—that enable room-temperature stable, ready-to-use drug formulations designed to improve patient convenience and compliance. The company generates revenue from product sales while pursuing licensing partnerships for its platform technologies, and relies on specialty pharmacies and third-party manufacturers to manage production and distribution of its complex, often orphan-designated therapies.